Key result
L-asparaginase linked to more severe anticoagulant and fibrinolytic declines in older children with ALL.
Observational (n=64)
Answers are grounded in this paper and cite their sources.
Alterations in haemostasis are frequently observed in children with acute lymphoblastic leukemia (ALL). It was the objective of this study to analyse age-related disturbances in coagulation and fibrinolysis parameters during the induction phase of the antileukemic treatment. Sixty-four children were classified by age into three groups (1-5, 6-10, 11-16 years), and studied during induction treatment of ALL including four weeks of dexamethasone, followed by two weeks tapering of dexamethasone during which 6,000 IU/m(2) native L-Asparaginase (total 4 doses) was administered intravenously twice weekly. Blood samples were collected immediately before each L-Asparaginase infusion to analyze procoagulant (fibrinogen, factor [F] II, FV, FVII, F IX, F X) and anticoagulant factors (antithrombin [AT], protein C, protein S), parameters of thrombin generation (F1+2, TAT) and fibrinolysis (alpha2-antiplasmin, plasminogen, PAP, D-dimer). Children were in a hypercoagulable state after four weeks of dexamethasone due to upregulation of coagulation parameters. Upregulation was highest in the two youngest age groups. During L-Asparaginase treatment the 11- to 16-year-olds showed lower values in procoagulant and, even more, in anticoagulant factor levels compared to the younger children. Activation markers of thrombin generation and fibrinolysis did not change over time during the study period. Decreased synthesis of alpha2-antiplasmin and plasminogen during L-Asparaginase treatment resulted in less potential of clot lysis by plasmin in children older than 11 years of age. In conclusion, a more severe decline of anticoagulant and fibrinolytic parameters in children between 11 and 16 years of age underline that these children are at higher risk of thrombosis during ALL induction treatment.
No takes yet. Share an insight, caveat, or question.
Hop et al. (2008) conducted an observational in Childhood acute lymphoblastic leukemia (n=64). Age group (11-16 years) during L-Asparaginase and dexamethasone induction vs. Younger age groups (1-5 and 6-10 years) was evaluated on Coagulation and fibrinolysis parameters (procoagulant factors, anticoagulant factors, thrombin generation, fibrinolysis). L-Asparaginase treatment (6,000 IU/m2 x 4 doses) in 64 ALL children caused a more severe decline in anticoagulant and fibrinolytic parameters in ages 11-16 vs 1-10 years.
Synapse has enriched 10 related papers. Consider them for comparative context: